Two momentum growth stocks that could help you retire early

Edward Sheldon profiles two stocks exhibiting strong upwards share price momentum at present.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s often said in the investment world that “the trend is your friend”. With that in mind, today I’m profiling two companies that have enjoyed strong share price momentum in recent years. Could this kind of momentum help you achieve your financial goals sooner?

NMC Health

Shares in FTSE 250-listed NMC Health (LSE: NMC) have trended up strongly over the last few years, rewarding long-term shareholders handsomely. Indeed, in the last year alone, the stock has risen from 1,033p to 2,106p, a gain of over 100%.

It’s not hard to see why when looking at the NMC’s financials. Revenue at the United Arab Emirates-based private healthcare services provider has surged from $551m to $1,221m over the last three years, a compound annual growth rate (CAGR) of 30%, and earnings during this period have climbed from 37 cents to 74 cents, a CAGR of 26%. FY2016 results released in March impressed the market, with revenue climbing 39% and basic earnings per share rising 61%.

Can the share price continue to rise from here? In my opinion, yes. NMC’s momentum looks set to continue this year with City analysts forecasting FY2017 revenue of $1,553m and earnings per share of 97 cents, growth of 27% and 31% respectively. Furthermore, mandatory healthcare insurance requirements in the Emirate of Dubai should boost patient volumes, and other regulatory changes such as the removal of IVF-related restrictions should provide tailwinds to the healthcare sector.

The stock trades on a forward-looking P/E of 28, which I wouldn’t classify as a bargain, however CEO BR Shetty stated in March that “we expect continued strong performance” this year, and as a result, I believe NMC’s share price momentum could continue from here.

Micro Focus International

Trading at a less demanding valuation is software specialist Micro Focus International (LSE: MCRO). Like NMC Health, Micro Focus has exhibited significant momentum in both its share price and its financials in recent years.

Revenue has climbed from $412m in FY2013 to $1,245m last year, a CAGR of 45% and the stock has registered a capital gain of 192% over the last three years, along with rising dividend payouts of 47 cents, 50 cents and 67 cents as well.

One risk to its momentum is the merger with Hewlett Packard Enterprise (HPE). Indeed, shares in Micro Focus plunged 11% last week, after HPE’s board said that preliminary indications were that revenue was down around 10% on a reported basis year-on-year in the quarter to 30 April. The decline was largely down to performance in the licence and professional services division and follows an 8% decline in the preceding quarter. This is clearly an issue to monitor closely. 

However with analysts forecasting group earnings of $1.76 per share for FY2017, a gain of 15% on last year, I reckon the shares have potential to keep rising in coming years. A forward looking P/E ratio of 18.1 seems reasonable for a tech stock, especially given the company’s successful acquisition history and the fact it has been one of the best performing stocks in the FTSE 100 over the last decade. As such, I believe Micro Focus offers an attractive risk/reward skew at present. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has no position in any shares mentioned. The Motley Fool UK has recommended Micro Focus. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

3 things investors should consider when building a £10k passive income

Ken Hall looks at three important considerations for investors looking to build a sizeable passive income for a better financial…

Read more »

Investing Articles

Here’s how much I need in a Stocks and Shares ISA to earn £50,000 of passive income a year

Is it realistic to one day generate £50k in dividend income from a Stocks and Shares ISA portfolio? This writer…

Read more »

Investing Articles

Up 124% in a year! But could the IAG share price still soar from here?

Christopher Ruane looks at why the IAG share price has more than doubled in the space of 12 months --…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

The genie’s out the bottle! After the US invests $500bn, are Warren Buffett’s AI fears warranted?

The new Trump administration's going full speed ahead with AI development, bringing to light fears Warren Buffett highlighted almost a…

Read more »

Investing Articles

The Burberry share price soars 15% after today’s results – is there more to come?

Harvey Jones is thrilled by the stellar performance of the Burberry share price this morning. This puts the lid on…

Read more »

Investing Articles

With £5,000 in UK shares, how much passive income could an investor expect?

A big question for UK investors is how much to pump into shares with the aim of achieving meaningful passive…

Read more »

Growth Shares

Greggs shares have tanked over the last 6 months and a broker says it’s time to sell

A City brokerage firm believes that Greggs shares could fall another 17% from here. Should investors give the stock a…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

Have I called the BP share price completely wrong?

Harvey Jones has taken advantage of the slump in the BP share price to pile into this FTSE 100 oil…

Read more »